A 2020 Vision of B-Cell Depletion

Moderator(s)

• 

  Jennifer Anolik, MD, PhD

  University of Rochester Medical Center

Speaker(s)

• RL

  R. John Looney, MD

  University of Rochester
• 

  Marko Radic, PhD

  University of Tennessee HSC
• 

  Falk Hiepe, MD

  Charité - Universitätsmedizin Berlin

B-cell-targeted therapies have become a mainstay of treatment for a range of autoimmune diseases, including rheumatoid arthritis, vasculitis and lupus. However, treatment responses to B-cell depletion with rituximab may be variable and have led to mixed results in diseases such as lupus. Although disease heterogeneity is likely one factor underlying this variable clinical response, another possibility is that certain subsets of B-cells contributing to disease pathogenesis are not adequately depleted. This session will summarize new approaches to B-cell targeting, including second-generation anti-CD20 antibodies, CAR-T therapy and proteasome inhibition.

Learning Objectives:

• Define why current B-cell targeted therapies may have limitations
• Review newer approaches to monoclonal antibody-mediated B-cell depletion, including second-generation anti-CD20 antibodies
• Describe emerging therapies to target B-cells and plasma cells, including CAR-T therapy and proteasome inhibition

Presentations:

• 5:00 PM – 5:15 PM ET

  Why Do We Need New Approaches for B Cell Depletion?
  R. John Looney, MD – University of Rochester
• 5:15 PM – 5:30 PM ET

  CAR-T Therapy: What’s the Potential in SLE and Other Immune-Mediated Diseases?
  Marko Radic, PhD – University of Tennessee HSC
• 5:30 PM – 5:45 PM ET

  Proteasome Inhibitors in the Treatment of Autoimmune Disease
  Falk Hiepe, MD – Charité - Universitätsmedizin Berlin
• 5:45 PM – 6:00 PM ET

  Q&A